Jiudian Pharmaceuticals recently announced that its dexketoprofen trometamol tablets have received marketing approval from China's National Medical Products Administration (NMPA). The product has become China's exclusive offering to pass  generic drug quality and efficacy consistency evaluation.
 

Dexketoprofen trometamol is developed by adding a ketone group to ibuprofen to form ketoprofen, then extracting the dextrorotary form of ketoprofen and combining it with trometamol. Compared with ibuprofen, dexketoprofen trometamol demonstrates:

• Stronger anti-inflammatory effects
• Better efficacy against cancer pain, postoperative pain and gouty arthritis
• Faster gastrointestinal absorption
• Quicker onset of action
• Lower toxicity
• Fewer adverse reactions

The compound delivers triple pharmacological effects including anti-inflammatory, antipyretic and analgesic functions.

Clinical data show the tablets are effective for treating mild-to-moderate pain of various causes, including:

• Joint pain from rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and gouty arthritis
• Other acute/chronic pain conditions like dysmenorrhea, toothache, postoperative pain, cancer pain, acute sprains or soft tissue contusions, and systemic pain caused by colds or fever

As a Category 3 new chemical drug, the product uses the company's self-developed APIs. With outstanding anti-inflammatory and analgesic efficacy plus higher safety, it represents a new option in the NSAID market. Against the backdrop of global aging, demand for NSAIDs continues to grow. China's anti-inflammatory and analgesic drug market exceeded 30 billion yuan in 2023, while similar products achieved annual sales exceeding $500 million in Europe and America. Leveraging its integrated API-formulation advantages, Jiudian achieves both cost control and quality improvement.

The newly approved product will complement Jiudian's existing portfolio including loxoprofen sodium gel patches, ketoprofen gel patches, ketoprofen gel, and loxoprofen sodium tablets to form combined oral-topical therapies for various acute/chronic pain conditions. Moving forward, Jiudian will continue to strengthen R&D innovation in the pain management field to deliver high-quality medicines to more patients.